Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

18.52
-0.9500-4.88%
Volume:305.21K
Turnover:5.71M
Market Cap:1.02B
PE:-13.54
High:20.08
Open:19.41
Low:18.31
Close:19.47
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:0.95
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3680
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:2.11
PE(LYR):-0.24

Loading ...

UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101

Reuters
·
Aug 14

Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate

Benzinga Earnings
·
Aug 14

Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses

Reuters
·
Aug 14

Aktis Oncology Q2 FY26 Net Loss Widens 33.15% to $24.1 Million

Reuters
·
Aug 14

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

THOMSON REUTERS
·
Aug 14

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Aktis Oncology Director Ken Herrmann Disposes of Common Shares Worth $119,256.78

Reuters
·
Jul 22

Aktis Oncology Insider Makes Notable Move With Fresh Stock Sale

TIPRANKS
·
Jul 21

Aktis Oncology Director Ken Herrmann Disposes of 3,065 Common Shares Worth $77,279.54

Reuters
·
Jul 21

Fifteen new option listings on July 15th

TIPRANKS
·
Jul 15

Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy Benchmark

TIPRANKS
·
Jul 15

Aktis Oncology is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 14

J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS)

TIPRANKS
·
Jul 14

Aktis Oncology price target raised to $33 from $30 at JPMorgan

TIPRANKS
·
Jul 14

Top Brass at Aktis Oncology Cash In With Major Stock Disposals

TIPRANKS
·
Jul 11

Aktis Oncology CMO Akos Czibere Disposes of Common Shares Worth $1.29 Million

Reuters
·
Jul 10

U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation

Reuters
·
Jun 16

Aktis Oncology initiated with a Strong Buy at Raymond James

TIPRANKS
·
Jun 16

Aktis Oncology posts investor presentation on miniprotein radioconjugate platform, lead Nectin-4 and B7-H3 programs

Reuters
·
Jun 11

Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 03